Cargando…

Biochemical effects of irbesartan in experimental diabetic nephropathy

BACKGROUND: Diabetic nephropathy (DN) is one of the most common causes of end-stage renal failure. The pathogenesis of progressive renal damage is multifactorial and the mechanism by which hyperglycemia causes microangiopathy in diabetic glomeruli is still poorly understood. Because the renin angiot...

Descripción completa

Detalles Bibliográficos
Autores principales: Vaishya, Richa, Singh, J., Lal, Harbans
Formato: Texto
Lenguaje:English
Publicado: Medknow Publications 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2846497/
https://www.ncbi.nlm.nih.gov/pubmed/20407554
http://dx.doi.org/10.4103/0253-7613.59922
_version_ 1782179485435559936
author Vaishya, Richa
Singh, J.
Lal, Harbans
author_facet Vaishya, Richa
Singh, J.
Lal, Harbans
author_sort Vaishya, Richa
collection PubMed
description BACKGROUND: Diabetic nephropathy (DN) is one of the most common causes of end-stage renal failure. The pathogenesis of progressive renal damage is multifactorial and the mechanism by which hyperglycemia causes microangiopathy in diabetic glomeruli is still poorly understood. Because the renin angiotensin system has been reported to be an important contributory factor in the pathophysiology of DN, exogenous administration of angiotensin II receptor antagonist may be beneficial in counteracting some biochemical or functional changes of DN. AIMS: The present study was therefore undertaken to evaluate the preventive role of irbesartan in streptozotocin (STZ)-induced DN in rats. METHODS AND MATERIAL: STZ-induced DN in rats was assessed biochemically by measuring urine volume, protein and electrolytes as well as blood urea and creatinine clearance. RESULTS: Marked hyperglycemia, polyuria, proteinuria and uremia along with a reduction in urine electrolytes and creatinine clearance were observed in STZ diabetic rats. Pre-treatment with irbesartan (20 mg/kg, p.o. 5 days prior to STZ and continued for 16 weeks) also significantly altered these parameters towards normal, except blood glucose. CONCLUSION: Pre-treatment with insulin reversed the parameters of DN. The data suggest that irbesartan prevents the development of STZ-induced DN in rats.
format Text
id pubmed-2846497
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Medknow Publications
record_format MEDLINE/PubMed
spelling pubmed-28464972010-04-06 Biochemical effects of irbesartan in experimental diabetic nephropathy Vaishya, Richa Singh, J. Lal, Harbans Indian J Pharmacol Research Article BACKGROUND: Diabetic nephropathy (DN) is one of the most common causes of end-stage renal failure. The pathogenesis of progressive renal damage is multifactorial and the mechanism by which hyperglycemia causes microangiopathy in diabetic glomeruli is still poorly understood. Because the renin angiotensin system has been reported to be an important contributory factor in the pathophysiology of DN, exogenous administration of angiotensin II receptor antagonist may be beneficial in counteracting some biochemical or functional changes of DN. AIMS: The present study was therefore undertaken to evaluate the preventive role of irbesartan in streptozotocin (STZ)-induced DN in rats. METHODS AND MATERIAL: STZ-induced DN in rats was assessed biochemically by measuring urine volume, protein and electrolytes as well as blood urea and creatinine clearance. RESULTS: Marked hyperglycemia, polyuria, proteinuria and uremia along with a reduction in urine electrolytes and creatinine clearance were observed in STZ diabetic rats. Pre-treatment with irbesartan (20 mg/kg, p.o. 5 days prior to STZ and continued for 16 weeks) also significantly altered these parameters towards normal, except blood glucose. CONCLUSION: Pre-treatment with insulin reversed the parameters of DN. The data suggest that irbesartan prevents the development of STZ-induced DN in rats. Medknow Publications 2009-12 /pmc/articles/PMC2846497/ /pubmed/20407554 http://dx.doi.org/10.4103/0253-7613.59922 Text en © Indian Journal of Pharmacology http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Vaishya, Richa
Singh, J.
Lal, Harbans
Biochemical effects of irbesartan in experimental diabetic nephropathy
title Biochemical effects of irbesartan in experimental diabetic nephropathy
title_full Biochemical effects of irbesartan in experimental diabetic nephropathy
title_fullStr Biochemical effects of irbesartan in experimental diabetic nephropathy
title_full_unstemmed Biochemical effects of irbesartan in experimental diabetic nephropathy
title_short Biochemical effects of irbesartan in experimental diabetic nephropathy
title_sort biochemical effects of irbesartan in experimental diabetic nephropathy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2846497/
https://www.ncbi.nlm.nih.gov/pubmed/20407554
http://dx.doi.org/10.4103/0253-7613.59922
work_keys_str_mv AT vaishyaricha biochemicaleffectsofirbesartaninexperimentaldiabeticnephropathy
AT singhj biochemicaleffectsofirbesartaninexperimentaldiabeticnephropathy
AT lalharbans biochemicaleffectsofirbesartaninexperimentaldiabeticnephropathy